Steven Anderson, PhD is the Chief Scientific Officer for LabCorp Drug Development. He has a PhD in Genetics from Iowa State University and his research interests include precision medicine, biomarker development, pharmacogenomics and companion diagnostics. He has published widely on these topics with a focus on applications in Oncology.
The PMWC 2022 Liquid Biopsy Showcase will provide a 15-minute time slot for selected liquid biopsy companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies that advance the development of screening tests for oncology, immunotherapy, and other areas, based on detection and identification of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating RNA, circulating microRNAs, or extracellular vesicle (exosomes).